위장 감염 검사 시장 규모 : 검사 유형별, 감염증 유형별, 최종 사용자별, 지역별 및 예측

Global Gastrointestinal Infection Testing Market Size And Forecast

Market capitalization in the gastrointestinal infection testing market has reached a significant USD 5.51 Billion in 2025 and is projected to maintain a strong 6.00% CAGR during the forecast period from 2027 to 2033. A company-wide policy adopting multiplex molecular diagnostic integration runs as the strong main factor for great growth. The market is projected to reach a figure of USD 8.66 Billion by 2033, indicating a significant reassessment of the entire economic landscape.

Global Gastrointestinal Infection Testing Market OverviewGastrointestinal infection testing refers to the diagnostic processes used to detect pathogens responsible for infections within the gastrointestinal tract. These tests identify bacteria, viruses, and parasites present in clinical samples, most commonly stool, to determine the cause of symptoms such as diarrhea, abdominal pain, vomiting, and fever. The term defines a diagnostic category that includes laboratory-based and rapid detection methods used to confirm the presence of infectious agents affecting the digestive system.

In market research, gastrointestinal infection testing functions as a defined diagnostic segment that groups technologies, instruments, and reagents used for pathogen identification in gastrointestinal conditions. The category sets the scope for data tracking by focusing on tests designed specifically for enteric pathogens, allowing consistent classification across laboratories, hospitals, and diagnostic centers.

The gastrointestinal infection testing market is shaped by the ongoing need for accurate pathogen detection in clinical and public health settings. Demand is largely linked to disease surveillance, hospital diagnostics, and outbreak monitoring, where timely identification of infectious organisms guides treatment and containment measures. Procurement patterns often reflect laboratory capacity, regulatory testing standards, and diagnostic workflow efficiency rather than short-term fluctuations in patient volumes.

Global Gastrointestinal Infection Testing Market Drivers

The market drivers for the gastrointestinal infection testing market can be influenced by various factors. These may include:

Prevalence of Foodborne and Waterborne Gastrointestinal Infections: High prevalence of foodborne and waterborne gastrointestinal infections is stimulating demand for diagnostic testing systems, as early pathogen identification is projected to support clinical treatment decisions and public health containment strategies. Every year, foodborne diseases cause around 600 million illnesses and 420,000 deaths worldwide, affecting nearly one in every ten people. The growing incidence of bacterial and viral gastroenteritis across urban and rural populations is increasing laboratory testing volumes in healthcare facilities.

Emphasis on Rapid and Accurate Pathogen Identification in Clinical Care: Growing emphasis on rapid and accurate pathogen identification in clinical care supports the adoption of advanced gastrointestinal infection testing methods across diagnostic laboratories and hospital networks. Faster diagnostic turnaround times improve clinical management of acute gastrointestinal illnesses. Increased integration of automated laboratory workflows supports large-scale testing efficiency across centralized diagnostic centers.

Expansion of Public Health Surveillance and Disease Monitoring Programs: Increasing expansion of public health surveillance and disease monitoring programs is driving sustained use of gastrointestinal infection testing tools across national health systems and epidemiological laboratories. Structured monitoring of enteric disease outbreaks encourages systematic diagnostic testing within regional healthcare infrastructures.

Adoption of Multiplex Molecular Diagnostic Technologies: Rising adoption of multiplex molecular diagnostic technologies is accelerating testing efficiency in gastrointestinal infection detection, as simultaneous identification of multiple pathogens reduces diagnostic delays and laboratory workload. Expanded implementation of PCR-based multiplex assays is strengthening diagnostic precision across hospital laboratories. Growing preference for high-throughput testing methods is improving operational productivity within diagnostic service providers handling large patient sample volumes.

Global Gastrointestinal Infection Testing Market Restraints

Several factors act as restraints or challenges for the gastrointestinal infection testing market. These may include:

Cost of Advanced Molecular Diagnostic Systems: The high cost of advanced molecular diagnostic systems is restraining adoption across small and mid-sized diagnostic laboratories, as procurement budgets remain limited within cost-sensitive healthcare environments. Substantial capital allocation for automated analyzers and multiplex testing platforms is hindering installation across resource-limited clinical settings. Additional expenses associated with reagents, calibration materials, and laboratory infrastructure upgrades place financial pressure on healthcare providers.

Limited Laboratory Infrastructure in Developing Healthcare Systems: Limited laboratory infrastructure in developing healthcare systems is hampering widespread deployment of gastrointestinal infection testing technologies across regional medical facilities. Diagnostic laboratories with restricted equipment capacity face operational constraints when high sample volumes are received during outbreak periods.

Regulatory Compliance and Validation Requirements for Diagnostic Tests: Regulatory compliance and validation requirements for diagnostic tests are restraining the rapid commercialization of new gastrointestinal infection testing products across multiple geographic markets. Extensive clinical performance verification procedures extend product approval timelines within regulated healthcare environments. Documentation and quality certification requirements are increasing development costs for diagnostic manufacturers.

Sample Collection and Handling Challenges in Clinical Diagnostics: Sample collection and handling challenges in clinical diagnostics are hindering the operational efficiency of gastrointestinal infection testing procedures across healthcare laboratories. Improper specimen collection protocols reduce diagnostic accuracy during pathogen detection processes. Transportation delays and storage condition limitations affect sample integrity before laboratory analysis.

Global Gastrointestinal Infection Testing Market Segmentation Analysis

The Global Gastrointestinal Infection Testing Market is segmented based on Test Type, Infection Type, End-User, and Geography.

Gastrointestinal Infection Testing Market, By Test Type

In the gastrointestinal infection testing market, molecular tests lead adoption due to their high sensitivity and ability to quickly identify bacterial, viral, and parasitic pathogens. Immunoassays continue to see steady use for routine pathogen screening through antigen and antibody detection. Culture tests remain a core laboratory method for confirmatory identification and antimicrobial susceptibility analysis of bacterial infections. Rapid diagnostic tests are expanding quickly as point-of-care solutions that deliver faster results in emergency departments and outpatient settings. The market dynamics for each type are broken down as follows:

Molecular Tests: Molecular tests dominate the gastrointestinal infection testing market, as high analytical sensitivity and rapid pathogen detection support accurate identification of bacterial, viral, and parasitic agents within clinical samples. The expanding deployment of polymerase chain reaction-based platforms is resulting in substantial growth across hospital laboratories seeking reliable diagnostic confirmation for acute gastrointestinal illnesses. Increasing laboratory modernization initiatives are accelerating the procurement of automated molecular analyzers integrated with digital laboratory workflows.

Immunoassays: Immunoassays are witnessing increasing adoption, as antigen and antibody detection techniques are supporting routine screening for commonly reported enteric pathogens across clinical laboratories. Emerging diagnostic protocols emphasizing cost-efficient detection methods are maintaining steady utilization of enzyme-linked immunosorbent assays within mid-volume testing environments.

Culture Tests: Culture tests retain a foundational role in gastrointestinal infection diagnostics, as microbiological culture techniques support confirmatory identification and antimicrobial susceptibility assessment of bacterial pathogens. Dominated by established laboratory procedures, traditional culture-based testing remains widely used within clinical microbiology laboratories handling gastrointestinal infection investigations. The growing requirement for detailed pathogen characterization is sustaining laboratory reliance on culture methods during epidemiological surveillance activities.

Rapid Diagnostic Tests (RDTs): Rapid diagnostic tests are experiencing a surge in demand within gastrointestinal infection testing, as point-of-care diagnostic solutions support quick clinical decision-making across emergency departments and outpatient healthcare settings. Emerging interest in decentralized diagnostic services is increasing the deployment of portable rapid testing kits capable of delivering results within short timeframes.

Gastrointestinal Infection Testing Market, By Infection Type

In the gastrointestinal infection testing market, bacterial infections account for the largest share, as organisms are widely linked to foodborne illness and hospital-reported gastrointestinal cases. Viral infections are expanding in testing volumes due to pathogens that frequently cause acute gastroenteritis. Parasitic infections maintain steady testing demand, driven by organisms, with diagnostic screening supported by travel-related infection checks, waterborne parasite surveillance, and monitoring of immunocompromised patient groups. The market dynamics for each type are broken down as follows:

Bacterial Infections: Bacterial infections dominate the gastrointestinal infection testing market, as pathogens such as Salmonella, Escherichia coli, and Campylobacter are estimated to account for a large proportion of clinically reported gastrointestinal illness cases requiring laboratory confirmation. Heightened focus on food safety monitoring and hospital infection surveillance is strengthening demand for diagnostic assays designed for bacterial pathogen identification. Expanding public health reporting requirements are increasing laboratory testing for bacterial enteric infections across healthcare institutions.

Viral Infections: Viral infections are indicating growth in gastrointestinal infection testing, as pathogens such as norovirus, rotavirus, and adenovirus contribute significantly to acute gastroenteritis cases across pediatric and adult populations. Emerging vaccination monitoring programs and hospital infection control protocols are encouraging routine viral pathogen detection across diagnostic laboratories.

Parasitic Infections: Parasitic infections are maintaining steady growth, as organisms such as Giardia, Entamoeba histolytica, and Cryptosporidium remain relevant causes of gastrointestinal disease in several geographic regions. Heightened focus on travel-related infection screening is an increasing diagnostic evaluation for parasitic pathogens within clinical laboratories. Growing awareness regarding parasitic infection risks in immunocompromised patient groups encourages routine laboratory screening procedures.

Gastrointestinal Infection Testing Market, By End-User

In the gastrointestinal infection testing market, hospitals and clinics account for the largest share, as patients with acute gastrointestinal symptoms commonly undergo diagnostic evaluation in inpatient and outpatient settings. Diagnostic laboratories are growing steadily as centralized facilities process large testing volumes from hospitals, clinics, and public health programs using high-throughput molecular and immunoassay platforms. Research centers also contribute to the market through studies on enteric pathogens, disease patterns, and antimicrobial resistance. The market dynamics for each type are broken down as follows:

Hospitals and Clinics: Hospitals and clinics dominate the gastrointestinal infection testing market, as a large volume of patients presenting with acute gastrointestinal symptoms drives routine diagnostic evaluation within inpatient and outpatient care settings. Expanding hospital diagnostic infrastructure is strengthening the adoption of automated testing platforms integrated with clinical decision support workflows. Increasing clinical reliance on laboratory-supported treatment decisions supports continued demand for gastrointestinal infection testing services across hospital and clinic environments.

Diagnostic Labs: Diagnostic labs are experiencing substantial growth within the gastrointestinal infection testing market, as centralized laboratory facilities are projected to process large testing volumes originating from hospitals, clinics, and public health screening programs. Expanding laboratory service networks support high-throughput pathogen detection through automated molecular and immunoassay platforms.

Research Centers: Research centers are experiencing steady expansion in the gastrointestinal infection testing market, as scientific investigation of enteric pathogens and emerging infectious disease patterns requires advanced diagnostic platforms and specialized analytical tools. Expanding collaboration between public health organizations and research institutions is strengthening laboratory testing activities dedicated to gastrointestinal disease studies. Growing interest in antimicrobial resistance monitoring and pathogen evolution is encouraging the use of sophisticated testing methodologies in research programs.

Gastrointestinal Infection Testing Market, By Geography

In the gastrointestinal infection testing market, North America holds the leading share due to advanced healthcare systems, widespread laboratory automation, and strong adoption of multiplex molecular testing. Europe is showing steady growth, supported by structured healthcare networks and coordinated disease monitoring programs that encourage the use of automated molecular diagnostics across hospital laboratories. Asia Pacific is expanding rapidly as large population bases, improving healthcare infrastructure, and rising infectious disease surveillance increase testing demand across major urban healthcare hubs. Latin America is progressing steadily with improving laboratory capabilities and growing adoption of modern pathogen detection technologies. The Middle East and Africa are witnessing gradual growth as healthcare investments, expanding hospital laboratory infrastructure, and regional disease monitoring programs support the use of advanced diagnostic platforms across key countries. The market dynamics for each region are broken down as follows:

North America: North America dominates the gastrointestinal infection testing market, as advanced healthcare infrastructure and widespread laboratory automation support high diagnostic testing volumes across major medical centers in cities such as New York, Boston, Toronto, and Los Angeles. Heightened focus on infectious disease monitoring within hospital networks across states, including California, Texas, and Massachusetts, is increasing the adoption of multiplex molecular testing systems. Expanding clinical laboratory chains across Chicago and Houston are strengthen access to specialized gastrointestinal pathogen detection services.

Europe: Europe is experiencing growth, supported by structured healthcare systems and coordinated disease surveillance initiatives across countries such as Germany, France, and the United Kingdom. Diagnostic laboratories in cities including London, Berlin, and Paris are experiencing increasing adoption of automated molecular testing platforms within clinical microbiology departments. Expanding hospital diagnostic networks in Milan, Madrid, and Amsterdam drive testing capacity across regional healthcare systems.

Asia Pacific: Asia Pacific is experiencing rapid expansion in the gastrointestinal infection testing market, as large population bases and rising infectious disease surveillance programs are increasing diagnostic demand across urban healthcare hubs such as Tokyo, Beijing, Seoul, Mumbai, and Singapore. Expanding healthcare infrastructure across Chinese provinces, including Guangdong and Zhejiang, is increasing the installation of advanced diagnostic laboratory equipment. Growing diagnostic laboratory chains across Indian states, including Maharashtra, Tamil Nadu, and Karnataka, are projected to strengthen regional testing capacity.

Latin America: Latin America is witnessing steady growth in the gastrointestinal infection testing market, supported by improving healthcare infrastructure and increasing infectious disease monitoring programs across countries such as Brazil, Mexico, and Argentina. Diagnostic laboratories in cities including Sao Paulo, Mexico City, and Buenos Aires are adopting modern pathogen detection technologies to strengthen clinical diagnostic accuracy.

Middle East and Africa: The Middle East and Africa are experiencing gradual expansion, supported by increasing healthcare investment and strengthening infectious disease surveillance programs across key countries, including Saudi Arabia, the United Arab Emirates, and South Africa. Major healthcare centers in cities such as Riyadh, Dubai, Johannesburg, and Cape Town are increasing the adoption of modern clinical diagnostic platforms for gastrointestinal pathogen detection. Heightened focus on improving hospital laboratory infrastructure across provinces in South Africa and emirates within the United Arab Emirates supports regional testing capacity.

Key Players

• The competitive landscape is increasingly determined by how well players adjust to new consumer values, even though it is still based on brand equity and scale. Even though market consolidation continues to change the strategic map, supply chain ethics, scientific innovation in comfort, and verifiable eco-credentials are now the main areas of strategic differentiation.
• Key Players Operating in the Global Gastrointestinal Infection Testing Market
• Abbott Laboratories
• bioMerieux
• Thermo Fisher Scientific
• Becton Dickinson & Co. (BD)
• Danaher
• Roche Diagnostics
• Bio-Rad Laboratories
• DiaSorin
• Quest Diagnostics
• Siemens Healthineers

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA AGE GROUPS

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET OVERVIEW
• 3.2 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET ATTRACTIVENESS ANALYSIS, BY TEST TYPE
• 3.8 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET ATTRACTIVENESS ANALYSIS, BY INFECTION TYPE
• 3.9 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET ATTRACTIVENESS ANALYSIS, BY END-USER
• 3.10 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.11 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET, BY TEST TYPE (USD BILLION)
• 3.12 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET, BY INFECTION TYPE (USD BILLION)
• 3.13 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET, BY END-USER (USD BILLION)
• 3.14 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET, BY GEOGRAPHY (USD BILLION)
• 3.15 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET EVOLUTION
• 4.2 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE GENDERS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY TEST TYPE

• 5.1 OVERVIEW
• 5.2 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY TEST TYPE
• 5.3 MOLECULAR TESTS
• 5.4 IMMUNOASSAYS
• 5.5 CULTURE TESTS
• 5.6 RAPID DIAGNOSTIC TESTS (RDTS)

6 MARKET, BY INFECTION TYPE

• 6.1 OVERVIEW
• 6.2 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY INFECTION TYPE
• 6.3 BACTERIAL INFECTIONS
• 6.4 VIRAL INFECTIONS
• 6.5 PARASITIC INFECTIONS

7 MARKET, BY END-USER

• 7.1 OVERVIEW
• 7.2 GLOBAL GASTROINTESTINAL INFECTION TESTING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END-USER
• 7.3 HOSPITALS AND CLINICS
• 7.4 DIAGNOSTIC LABS
• 7.5 RESEARCH CENTERS

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 U.S.
  • 8.2.2 CANADA
  • 8.2.3 MEXICO
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 U.K.
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 JAPAN
  • 8.4.3 INDIA
  • 8.4.4 REST OF ASIA PACIFIC
• 8.5 LATIN AMERICA
  • 8.5.1 BRAZIL
  • 8.5.2 ARGENTINA
  • 8.5.3 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 UAE
  • 8.6.2 SAUDI ARABIA
  • 8.6.3 SOUTH AFRICA
  • 8.6.4 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 KEY DEVELOPMENT STRATEGIES
• 9.3 COMPANY REGIONAL FOOTPRINT
• 9.4 ACE MATRIX
  • 9.4.1 ACTIVE
  • 9.4.2 CUTTING EDGE
  • 9.4.3 EMERGING
  • 9.4.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 OVERVIEW
• 10.2 ABBOTT LABORATORIES
• 10.3 BIOMERIEUX
• 10.4 THERMO FISHER SCIENTIFIC
• 10.5 BECTON DICKINSON & CO. (BD)
• 10.6 DANAHER
• 10.7 ROCHE DIAGNOSTICS
• 10.8 BIO-RAD LABORATORIES
• 10.9 DIASORIN
• 10.10 QUEST DIAGNOSTICS
• 10.11 SIEMENS HEALTHINEERS